A Phase I Dose Escalation Study of the mTOR Inhibitor Everolimus (RAD001) and Erlotinib Concurrently With Radiation Therapy in the Re-Irradiation Setting for Head and Neck Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT01332279

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:39:14.388395+00:00

Published At

2023-04-04T00:00:00+00:00

Record Updated At

2023-04-04

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Salivary Gland Squamous Cell Carcinoma", "Tongue Cancer"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2023-04-04"

protocolSection.identificationModule.nctId

"NCT01332279"

protocolSection.identificationModule.officialTitle

"A Phase I Dose Escalation Study of the mTOR Inhibitor Everolimus (RAD001) and Erlotinib Concurrently With Radiation Therapy in the Re-Irradiation Setting for Head and Neck Cancer"

protocolSection.statusModule.overallStatus

"WITHDRAWN"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Recurrent Metastatic Squamous Neck Cancer With Occult Primary (protocolSection.conditionsModule.conditions)
• Recurrent Salivary Gland Cancer (protocolSection.conditionsModule.conditions)
• Recurrent Squamous Cell Carcinoma of the Hypopharynx (protocolSection.conditionsModule.conditions)
• Recurrent Squamous Cell Carcinoma of the Larynx (protocolSection.conditionsModule.conditions)
• Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity (protocolSection.conditionsModule.conditions)
• Recurrent Squamous Cell Carcinoma of the Oropharynx (protocolSection.conditionsModule.conditions)
• Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity (protocolSection.conditionsModule.conditions)
• Recurrent Verrucous Carcinoma of the Larynx (protocolSection.conditionsModule.conditions)
• Recurrent Verrucous Carcinoma of the Oral Cavity (protocolSection.conditionsModule.conditions)
• Salivary Gland Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
• Tongue Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.